MA
MAZE.US Maze Therapeutics, Inc. Common Stock
- Market cap
- USD 1.88B
- P/E
- -
- P/B
- 4.38x
- ROE
- -36.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MAZE.US undervalued?
Graham numberThe Graham number of Maze Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Maze Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Maze Therapeutics, Inc. Common Stock yet.
Maze Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatme…
Full company profileMaze Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Maze Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 168M | 0.00 | 26.7M |
| Gross Profit | -3.82M | -4.09M | 168M | -2.40M | - |
| Operating Income | -111M | -98.6M | 57.6M | -143M | -168M |
| EBITDA | -111M | -96.3M | 56.7M | -129M | -151M |
| Net Income | -115M | -100M | 52.2M | -131M | -156M |
| EPS | -2.63 | -2.29 | 1.19 | -3.05 | -2.56 |
| Balance Sheet | |||||
| Total Assets | 150M | 71.5M | 241M | 397M | 512M |
| Total Liabilities | 48.5M | 61.5M | 43.6M | 42.2M | 83.0M |
| Shareholders' Equity | 101M | 10.1M | 197M | 355M | 429M |
| Cash & Short-term Investments | 99.9M | 29.2M | 197M | 342M | 390M |
| Total Debt | 32.1M | 49.6M | 26.6M | 23.3M | 59.6M |
| Cash Flow | |||||
| Operating Cash Flow | -99.2M | -86.8M | 76.0M | -112M | -116M |
| Capital Expenditure | 1.97M | 441K | 1.15M | 794K | 651K |
| Free Cash Flow | -101M | -87.3M | 74.8M | -113M | -117M |
| Ratios | |||||
| ROE | -113.3% | -998.8% | 26.5% | -36.9% | -36.4% |
| ROA | -76.6% | -140.4% | 21.7% | -33.0% | -30.5% |
| Net Profit Margin | - | - | 31.2% | - | -584.5% |
| Debt to Equity | 0.32x | 4.94x | 0.14x | 0.07x | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Maze Therapeutics, Inc. Common Stock dividends
Maze Therapeutics, Inc. Common Stock has not paid dividends in the last 4 fiscal years.
Who owns Maze Therapeutics, Inc. Common Stock
- Insiders 1.76%
- Institutions 98.24%
- Public & others 0.00%
- Shares outstanding 54.7M
- Free float 36.0M
Top funds holding MAZE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.41M | 2.50% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 889K | 1.58% | 0.00% | Oct 2026 |
| Fidelity Select Biotechnology | 787K | 1.40% | +0.64% | Aug 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 693K | 1.23% | -0.37% | Jun 2026 |
| JPMorgan Small Cap Growth A | 532K | 0.94% | -0.61% | Sep 2026 |
| Fidelity Small Cap Index | 387K | 0.69% | +0.31% | Aug 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 335K | 0.59% | +2.88% | Oct 2026 |
| JNL/T. Rowe Price Capital Appreciation A | 291K | 0.52% | +35.02% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 279K | 0.49% | -0.38% | Oct 2026 |
| Candriam Eqs L Biotech C USD Cap | 278K | 0.49% | 0.00% | Apr 2026 |
| iShares Biotechnology ETF | 267K | 0.47% | -0.19% | Oct 2026 |
| abrdn Healthcare Investors | 253K | 0.45% | +70.90% | Oct 2026 |
| Vanguard Russell 2000 ETF | 205K | 0.36% | +1.21% | Sep 2026 |
| International Biotechnology Ord | 200K | 0.35% | 0.00% | Jul 2026 |
| Schwab US Small-Cap ETF™ | 196K | 0.35% | +0.23% | Oct 2026 |
| BlackRock Health Sciences Opps Inv A | 184K | 0.33% | 0.00% | Sep 2026 |
| abrdn Life Sciences Investors | 178K | 0.32% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 174K | 0.31% | +24.43% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 173K | 0.31% | 0.00% | Sep 2026 |
| BGF World Healthscience A2 | 172K | 0.30% | 0.00% | Jul 2026 |
Top institutions holding MAZE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 5.03M | 8.92% | +10.20% | Jun 2026 |
| TRV GP IV, LLC | 4.47M | 7.93% | 0.00% | Jun 2026 |
| ARCH VENTURE CORP | 4.12M | 7.30% | 0.00% | Jun 2026 |
| Deep Track Capital, LP | 3.73M | 6.61% | +7.33% | Jun 2026 |
| BlackRock Inc | 3.50M | 6.21% | +36.27% | Jun 2026 |
| Jupiter Topco LLC | 3.41M | 6.04% | 0.00% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 2.60M | 4.61% | 0.00% | Jun 2026 |
| Logos Global Management LP | 1.94M | 3.43% | +56.68% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.78M | 3.15% | +23.86% | Jun 2026 |
| VR Adviser, LLC | 1.60M | 2.84% | 0.00% | Jun 2026 |
| Alphabet Inc | 1.39M | 2.46% | 0.00% | Jun 2026 |
| BRAIDWELL LP | 1.14M | 2.02% | 0.00% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 1.11M | 1.96% | +197.00% | Jun 2026 |
| FMR Inc | 1.06M | 1.87% | +22.30% | Jun 2026 |
| General Catalyst Group Management, LLC | 1.04M | 1.84% | 0.00% | Jun 2026 |
| State Street Corp | 998K | 1.77% | +56.67% | Jun 2026 |
| JPMorgan Chase & Co | 964K | 1.71% | +1,549.40% | Jun 2026 |
| Driehaus Capital Management LLC | 955K | 1.69% | +50.10% | Jun 2026 |
| TRV GP V, LLC | 951K | 1.68% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 915K | 1.62% | +194.42% | Jun 2026 |
Maze Therapeutics, Inc. Common Stock company profile
- Company name
- Maze Therapeutics, Inc. Common Stock
- Ticker
- MAZE.US
- Exchange
- USA Stocks
- Listed since
- Jan 31, 2025
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 141
- Fiscal year end
- December
- Address
- 171 Oyster Point Blvd, South San Francisco, CA, United States, 94080
- Phone
- 650 850 5070
- Website
- mazetx.com
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Maze Therapeutics, Inc. Common Stock management
10- Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D.CEO & Director · born 1976
- Mr. Misbah Tahir CPACFO & Principal Accounting Officer · born 1975
- Dr. Harold S. Bernstein M.D., Ph.D.President of Research & Development and Chief Medical Officer · born 1960
- Mr. Vipin VijayakumarSenior Vice President of Technology and Business Operations
- Mr. Maarten HoekChief Scientific Officer
- Ms. Courtney J. Phillips J.D.General Counsel & Corporate Secretary · born 1975
- Mr. Matt KrauseSenior Vice President of Human Resources
- Mr. Atul DandekarChief Strategy & Business Officer · born 1972
- Ms. Nazila HabibizadSenior Vice President of Technical Operations & Supply Chain · born 1963
- Mr. Winston TseSenior Vice President of Drug Discovery